State Key Laboratory of Veterinary Etiological Biology, Key Laboratory of Veterinary Parasitology of Gansu Province, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Lanzhou, Gansu Province 730046, PR China.
BMC Infect Dis. 2014 Sep 6;14:487. doi: 10.1186/1471-2334-14-487.
Toxoplasma gondii can infect all warm-blooded animals including humans. Infection with T. gondii is probably the leading cause of posterior uveitis in humans and the most comment route of transmission is raw and undercooked meat from infected animals. T. gondii calcium-dependent protein kinase 1 (TgCDPK1) plays a critical role in direct parasite motility, host-cell invasion, and egress.
We constructed a DNA vaccine expressing TgCDPK1 inserted into eukaryotic expression vector pVAX I and evaluated the immune protection induced by pVAX-CDPK1 in Kunming mice. Mice immunized with pVAX-CDPK1 intramuscularly and/or with a plasmid encoding IL-15 and IL-21 (pVAX-IL-21-IL-15). The immune responses were analyzed including lymphoproliferative assay, cytokine, antibody measurements, lymphocyte surface markers by flow cytometry and protective efficacy were measured as survival and cysts numbers after challenge 1 to 2 months post vaccination.
Immunization with pVAX-CDPK1 or pVAX-IL-21-IL-15 alone developed strong humoral responses and Th1 type cellular immune responses, and the significantly (P < 0.05) increase of both the percentages of CD4+ and CD8+ T cells compared with all the controls (blank control, PBS, and pVAX). Co-injection of pVAX-IL-21-IL-15 significantly increased humoral and cellular immune responses compared to the group of pVAX-CDPK1 or pVAX-IL-21-IL-15. Challenge experiments showed that co-administration of pVAX-IL-21-IL-15 and pVAX-CDPK1 significantly (P < 0.05) increased survival time (19.2 ± 5.1 days) compared with pVAX-CDPK1 (17.3 ± 4.3 days) or pVAX-IL-21-IL-15 (12.0 ± 2.0 days) alone, and pVAX-IL-21-IL-15 + pVAX-CDPK1 significantly reduced the number of brain cysts (72.7%) in contrast to pVAX-ROP13 (45.7%) or pVAX-IL-21-IL-15 alone (43.6%).
TgCDPK1 is identified to be a promising vaccine candidate for inducing a strong humoral and cellular response against T. gondii infection, and thus synergistic of mIL-21 and mIL-15 can induce non-specific immune responses, but also facilitate specific humoral as well as cellular immune responses elicited by DNA vaccine against acute and chronic T. gondii infection in mice.
刚地弓形虫可感染所有温血动物,包括人类。弓形虫感染可能是人类后葡萄膜炎的主要原因,最常见的传播途径是食用来自受感染动物的生的或未煮熟的肉。刚地弓形虫钙依赖蛋白激酶 1(TgCDPK1)在寄生虫的直接运动、宿主细胞侵袭和逸出中起着关键作用。
我们构建了一种表达 TgCDPK1 的 DNA 疫苗,插入真核表达载体 pVAX I,并在昆明小鼠中评估了 pVAX-CDPK1 诱导的免疫保护作用。通过肌肉内免疫 pVAX-CDPK1 和/或质粒编码 IL-15 和 IL-21(pVAX-IL-21-IL-15)对小鼠进行免疫。通过淋巴细胞增殖试验、细胞因子、抗体测量、流式细胞术检测淋巴细胞表面标志物来分析免疫反应,并在接种后 1 至 2 个月进行攻毒后测量存活率和囊包数量来评估保护效果。
单独免疫 pVAX-CDPK1 或 pVAX-IL-21-IL-15 可产生强烈的体液和 Th1 型细胞免疫反应,与空白对照、PBS 和 pVAX 相比,CD4+和 CD8+T 细胞的百分比均显著增加(P<0.05)。与 pVAX-CDPK1 或 pVAX-IL-21-IL-15 组相比,共注射 pVAX-IL-21-IL-15 可显著增加体液和细胞免疫反应。攻毒实验表明,与 pVAX-CDPK1(17.3±4.3 天)或 pVAX-IL-21-IL-15(12.0±2.0 天)单独相比,pVAX-IL-21-IL-15 和 pVAX-CDPK1 共同给药可显著(P<0.05)延长存活时间(19.2±5.1 天),pVAX-IL-21-IL-15 + pVAX-CDPK1 可使脑囊包数量减少 72.7%(与 pVAX-ROP13 相比为 45.7%)或与 pVAX-IL-21-IL-15 单独相比减少 43.6%。
TgCDPK1 被鉴定为一种有前途的疫苗候选物,可诱导针对刚地弓形虫感染的强烈体液和细胞反应,因此 mIL-21 和 mIL-15 的协同作用不仅可以诱导非特异性免疫反应,还可以促进针对急性和慢性刚地弓形虫感染的 DNA 疫苗诱导的特异性体液和细胞免疫反应。